A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model

INTRODUCTION: Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising strategy for treating Alzheimer’s disease (AD). One drawback in the past was that clinical trial approval was withheld because of speculation that the Aβ42 vaccine induces CD4(+) T cell...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wang, Shuang, Yu, Yang, Geng, Shuang, Wang, Dongmei, Zhang, Li, Xie, Xiaoping, Wu, Bing, Li, Chaofan, Xu, Hanqian, Li, Xiaolin, Hu, Yanxin, Zhang, Lianfeng, Kaether, Christoph, Wang, Bin
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2014
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4075150/
https://ncbi.nlm.nih.gov/pubmed/24987466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt256
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky